Eton Pharmaceuticals Amends Credit Agreement, Eases Debt Terms

Eton Pharmaceuticals ( (ETON) ) has shared an update.

On April 9, 2026, Eton Pharmaceuticals, Inc. amended its credit agreement with SWK Funding LLC, reducing the interest rate from SOFR plus 6.75% to SOFR plus 6.55% and lowering the SOFR floor from 5.0% to 2.75%. The company also extended the interest-only period on the loan to November 2026, gained flexibility to begin principal payments in May or November 2026, and preserved the December 2027 maturity date, improving its financing terms without incurring amendment fees.

These changes ease near-term debt service obligations and provide Eton Pharmaceuticals with additional financial flexibility, which could support ongoing operations and strategic initiatives while maintaining its existing long-term repayment schedule.

The most recent analyst rating on (ETON) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on Eton Pharmaceuticals stock, see the ETON Stock Forecast page.

Spark’s Take on ETON Stock

According to Spark, TipRanks’ AI Analyst, ETON is a Neutral.

The score is driven primarily by improving financial performance and a constructive earnings outlook (strong 2026 guidance with expanding margins), supported by bullish price trend signals. Offsetting factors are an overheated momentum setup (RSI/Stoch elevated) and weak valuation support given the negative P/E and no dividend yield.

To see Spark’s full report on ETON stock, click here.

More about Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing prescription drugs, with a business model that relies in part on access to specialized credit facilities to support its operations and growth initiatives.

Average Trading Volume: 348,465

Technical Sentiment Signal: Buy

Current Market Cap: $710.8M

For an in-depth examination of ETON stock, go to TipRanks’ Overview page.